Breast Cancer Archives - IPN Delhi India

abemaciclib tablets

abemaciclib tablets,
for oral use Initial U.S. Approval: 2017

Verzenio (abemaciclib) is a medication indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer.

Facts about abemaciclib tablets

Disease Indications-Breast Cancer
Manufacturer-Lilly
Usage-Oral
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “abemaciclib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

ado-trastuzumab emtansine for injection

Breast Cancer

ado-trastuzumab emtansine for injection,
for intravenous use Initial U.S. Approval: {YYYY}

Kadcyla (trastuzumab emtansine) is a cancer medicine that is used to treat advanced or metastatic HER2-positive breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane.

Facts about ado-trastuzumab emtansine for injection

Disease Indications-Breast Cancer
Manufacturer-Genentech, Inc
Usage-Intravenous
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “ado-trastuzumab emtansine for injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

alpelisib tablets

Breast Cancer

alpelisib tablets, for oral use Initial U.S. Approval: 2019

As specified in the prescribing information, alpelisib tablets is indicated for the treatment of Breast Cancer. Piqray (alpelisib) is a medication used in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CAmutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Facts about alpelisib tablets

DISEASE INDICATIONS-Breast Cancer
MANUFACTURER-Novartis
USAGE-Oral
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “alpelisib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

atezolizumab injection

Gastrointestinal, Breast Cancer, Lung

atezolizumab injection
for intravenous use Initial U.S. Approval: 2016

Tecentriq (atezolizumab) is a medication used for the treatment of locally advanced or metastatic urothelial carcinoma, for the treatment of metastatic non-small cell lung cancer (NSCLC), and for the treatment of advanced triple negative breast cancer (TNBC).

Facts about atezolizumab injection

DISEASE INDICATIONS-Urothelial Carcinoma, Breast Cancer, Lung Cancer
MANUFACTURER-Roche Registration Limited
USAGE-Intravenous
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “atezolizumab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

capecitabine tablets

Colon, Breast Cancer, Esophageal, Pancreatic, Stomach

capecitabine tablets
for oral use Initial U.S. Approval: 1998

capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuv ant Colon Cancer –Patients with Dukes’ C colon cancer • Metastatic Colorectal Cancer –First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer –In combination with docetaxel after failure of prior anthracyclinecontaining therapy –As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen

Facts about capecitabine tablets

Approval Date: 1998
Proprietary Name: On Request
Active Ingredient(s): capecitabine tablets
Dosage Forms And Strengths: Tablets: 150 mg and 500 mgTablets: 150 mg and 500 mg
Company: Genentech
Current indications: Breast cancer, Colorectal cancer, Pancreatic adenocarcinoma, Stomach (gastric) cancer, esophageal cancer, or gastroesophageal junction cancer in adults, Stomach (gastric) cancer or gastroesophageal junction cancer in adults.
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import capecitabine tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Capivasertib Tablets, for oral use Initial U.S. Approval: 2023

Breast Cancer

Capivasertib Tablets, for oral use Initial U.S. Approval: 2023

Truqap is used to treat breast cancers that are:

metastatic and have grown after treatment with at least one hormonal therapy medicine.
locally advanced and have grown within the year after adjuvant treatment was complete; adjuvant treatments are treatments given after breast cancer surgery.

Approval Date: 2023
Proprietary Name: TRUQAP
Active Ingredient(s): capivasertib
FDA-approved use: To treat patients with HER2-negative breast cancer
Dosage Form: Tablets
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “Capivasertib Tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

docetaxel Injection

Prostate, Breast Cancer, Gastrointestinal, Head And Neck, Lung

docetaxel Injection
for intravenous use Initial U.S. Approval: 1996

docetaxel Injection is a prescription anticancer medicine used to treat certain people with: • breast cancer • non-small cell lung cancer • prostate cancer • stomach cancer • head and neck cancer It is not known if TAXOTERE is effective in children. What are the ingredients in TAXOTERE? Active ingredient: docetaxel Inactive ingredients: polysorbate 80 and dehydrated alcohol solution.

Facts about docetaxel Injection

Approval Date: 1996
Proprietary Name: On Request
Active Ingredient(s): docetaxel Injection
Dosage Forms And Strengths: Injection: One-vial TAXOTERE: Single-dose vials 20 mg/mL and 80 mg/4 mL
Company: sanofi aventis
Current indications:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import docetaxel Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

eflapegrastim-xnst injection

Breast Cancer, Lung

eflapegrastim-xnst injection
for subcutaneous use Initial U.S. Approval: 2022

Rolvedon (eflapegrastim-xnst) is a leukocyte growth factor used to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. FDA-approved use: To decrease the incidence of infection in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia

Facts about eflapegrastim-xnst injection

Approval Date: 9/9/2022
Proprietary Name: Rolvedon
Active Ingredient(s): eflapegrastim-xnst
Dosage Form: Injection
DISEASE INDICATIONS-Breast Cancer, Lung Cancer
MANUFACTURER-Spectrum Pharmaceuticals, Inc.
USAGE-Intravenous
MEDICINE APPROVED BY-Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “eflapegrastim-xnst injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

elacestrant tablets

Breast Cancer

elacestrant tablets,
For oral use Initial U.S. Approval: 2023

As specified in the prescribing information, Orserdu (elacestrant) is indicated for the treatment of breast cancer disease. As per highlights Of prescribing information (elacestrant) tablets is an estrogen receptor antagonist indicated for: • treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Facts about elacestrant tablets

Disease Indications: Breast Cancer
Dosage Forms And Strengths: Tablets: 345 mg and 86 mg
Manufacturer: Stemline Therapeutics
Usage: Oral
Medicine Approved By: Food and Drug Administration (FDA)
Orserdu (elacestrant) was approved by the FDA in January 2023

Extra Information:

Full prescribing information [FDA]: Orserdu (elacestrant) [PDF] Stemline Therapeutics, Inc., January 2023.
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer FDA, January 2023

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “elacestrant tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

everolimus tablets

Breast Cancer, Gastrointestinal, Kidney, Lung

everolimus tablets for oral suspension
Initial U.S. Approval: 2009

Afinitor (everolimus) is a medication used to treat patients with advanced HR+, HER2- breast cancer; progressive neuroendocrine tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis.

Facts about everolimus tablets

Disease Indications-Breast Cancer, Gastric Cancer, Kidney Cancer, Lung Cancer, Intestinal Cancer
Manufacturer-Novartis
Usage-Intravenous
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada Pharmaceuticals and Medical Devices Agency (PMDA) Therapeutic Goods Administration (TGA).
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “everolimus tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

List of Oncology Medication For

Breast Cancer

Indian Pharma Network

M: +9891296838 / 9811747774E: med@indianpharmanetwork.co.in

abemaciclib tablets, for oral use Initial U.S. Approval: 2017

Facts about abemaciclib tablets

Access the best support services globally

ado-trastuzumab emtansine for injection, for intravenous use Initial U.S. Approval: {YYYY}

Facts about ado-trastuzumab emtansine for injection

Access the best support services globally

alpelisib tablets, for oral use Initial U.S. Approval: 2019

Access the best support services globally

atezolizumab injection for intravenous use Initial U.S. Approval: 2016

Facts about atezolizumab injection

Access the best support services globally

capecitabine tablets for oral use Initial U.S. Approval: 1998

Facts about capecitabine tablets

Access the best support services globally

Capivasertib Tablets, for oral use Initial U.S. Approval: 2023

Access the best support services globally

docetaxel Injection for intravenous use Initial U.S. Approval: 1996

Facts about docetaxel Injection

Access the best support services globally

eflapegrastim-xnst injection for subcutaneous use Initial U.S. Approval: 2022

Facts about eflapegrastim-xnst injection

Access the best support services globally

elacestrant tablets, For oral use Initial U.S. Approval: 2023

Facts about elacestrant tablets

Extra Information:

Access the best support services globally

everolimus tablets for oral suspension Initial U.S. Approval: 2009

Facts about everolimus tablets

Access the best support services globally

Contact Info

Query Form For Medications

Indian Pharma Network (IPN), New Delhi. India

M: +9891296838 / 9811747774
E: med@indianpharmanetwork.co.in

abemaciclib tablets,
for oral use Initial U.S. Approval: 2017

ado-trastuzumab emtansine for injection,
for intravenous use Initial U.S. Approval: {YYYY}

atezolizumab injection
for intravenous use Initial U.S. Approval: 2016

capecitabine tablets
for oral use Initial U.S. Approval: 1998

docetaxel Injection
for intravenous use Initial U.S. Approval: 1996

eflapegrastim-xnst injection
for subcutaneous use Initial U.S. Approval: 2022

elacestrant tablets,
For oral use Initial U.S. Approval: 2023

everolimus tablets for oral suspension
Initial U.S. Approval: 2009